S. Maehara

发表

Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist.

M. Hata, A. Satoh, Yasushi Nagatomi, 2009, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of a New, Orally Active and Potent Allosteric Metabotropic Glutamate Receptor 1 Antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)

Hisashi Ohta, Hiroshi Kawamoto, Satoru Ito, 2007, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological characterization of a new, orally active and potent allosteric mGluR1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6 -dihydropyridine-1(2H)-carboxamide (FTIDC)

G. Suzuki, Toshifumi Kimura, S. Maehara, 2007 .

Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders.

M. Hata, A. Satoh, Yasushi Nagatomi, 2009, Bioorganic & medicinal chemistry letters.

Displacing effects of chenodeoxycholic acid, ursodeoxycholic acid and sulfadimethoxine on plasma protein binding of tolbutamide.

S. Maehara, S. Watanabe, Y. Nakata, 1985, Journal of pharmacobio-dynamics.

Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878

T. Takeuchi, S. Maehara, Chika Higashi, 2020, Neuropsychopharmacology reports.

Orexin 2 receptor is involved in orexin A-induced hyperlocomotion in rats

S. Maehara, Takumi Ota, Junji Furukawa, 2019, Pharmacological reports : PR.

Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice.

S. Maehara, H. Hikichi, A. Satow, 2010, European Journal of Pharmacology.

Unique Antipsychotic Activities of the Selective Metabotropic Glutamate Receptor 1 Allosteric Antagonist 2-Cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one

T. Murai, S. Ozaki, M. Hata, 2009, Journal of Pharmacology and Experimental Therapeutics.

Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.

M. Hata, A. Satoh, Yasushi Nagatomi, 2008, Bioorganic & Medicinal Chemistry.

Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain

T. Takeuchi, S. Maehara, Toshiya Endo, 2020, Pharmacology research & perspectives.

Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

S. Maehara, Kazunari Nakao, Y. Miyazaki, 2016, Pharmacology research & perspectives.

Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia

S. Okuda, S. Maehara, H. Hikichi, 2008, Pharmacology Biochemistry and Behavior.

Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice—Possible involvement of muscarinic receptors

S. Maehara, H. Hikichi, H. Ohta, 2011, Brain Research.

Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions

S. Okuda, S. Maehara, H. Ohta, 2011, Brain Research Bulletin.

Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antago

S. Ito, G. Suzuki, Toshifumi Kimura, 2008, Journal of Pharmacology and Experimental Therapeutics.

Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.

Takao Inoue, S. Ozaki, M. Hata, 2009, Journal of pharmacological sciences.

Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic‐like effects without affecting cognitive enhancement and cataleptic effects in rats

S. Maehara, Keita Arakawa, 2020, Neuropsychopharmacology reports.

Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.

S. Maehara, Kazunari Nakao, S. Furusako, 2017, European journal of pharmacology.

Dopamine D1 signaling involvement in the effects of the phosphodiesterase 10A inhibitor, PDM-042 on cognitive function and extrapyramidal side effect in rats

S. Maehara, Kazunari Nakao, Keita Arakawa, 2017, Behavioural Brain Research.

A Selective Phosphodiesterase 10A Inhibitor Reduces L‐Dopa‐Induced Dyskinesias in Parkinsonian Monkeys

S. Papa, S. Maehara, G. Beck, 2018, Movement disorders : official journal of the Movement Disorder Society.

Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents.

S. Okuda, T. Murai, M. Hata, 2010, European journal of pharmacology.

Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

S. Maehara, Natsuko Yuge, Keita Arakawa, 2020, Pharmacological Reports.

Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor.

T. Murai, S. Maehara, H. Hikichi, 2008, European journal of pharmacology.

A Selective Phosphodiesterase 10A Inhibitor Reduces L‐Dopa‐Induced Dyskinesias in Parkinsonian Monkeys

S. Papa, S. Maehara, G. Beck, 2018, Movement disorders : official journal of the Movement Disorder Society.